Meeting
2011 ASCO Annual Meeting
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2.
Authors
James Yao
University of Texas M. D. Anderson Cancer Center
James Yao , Sergio Ricci , Robert Winkler , Valentine Jehl , Marianne Pavel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Other GI Cancer
Clinical Trial Registration Number
NCT00412061
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4011)
Abstract #
4011
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET).
First Author: James C. Yao
Poster
2011 ASCO Annual Meeting
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial.
First Author: Lowell Anthony
Poster
2011 ASCO Annual Meeting
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2.
First Author: Edward Wolin
Poster
2014 Gastrointestinal Cancers Symposium
Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET): A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data.
First Author: Jonathan R. Strosberg